Appl. No. 10/073,735

Reply dated November 1, 2004

Reply to Notice to Comply mailed October 6, 2004

Application No.

10/073,735

Applicant:

Anne Chew et al.

Confirmation No.

4233

Filed:

February 11, 2002

Title:

Haplotypes of the FCER1A Gene

Art Unit:

1634

Examiner:

Diana B. Johannsen

Attorney Docket No.: MWH-0007US

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450



RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

This paper is submitted in response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated October 6, 2004.

Amendment to Sequence Listing

A compliant substitute Sequence listing is submitted herewith that corrects the typographic error at line 1239 of the Sequence Listing filed with the application that is noted in the Sequence Error Report. The correction to read T or C is supported by the Y in SEQ ID NO:114 at position 150 of the sequence listing as filed. The substitute Sequence Listing is provided as a paper copy and in computer readable form, along with the required Statement concerning the content of the substitute Sequence Listing.

Applicants request entry of this substitute Sequence Listing into the specification.

Respectfully submitted,

Tel. No. 203-786-3468


s.shaner@genaissance.com

Sandra L. Shaner

Genaissance Pharmaceuticals, Inc.

Five Science Park

New Haven, CT 06511



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Anne Chew et al.

Group No.: 1634

Application No.:

10/073,735

Examiner: Diana B. Johannsen

Filed:

February 11, 2002

Box Sequence Commissioner for Patents Arlington, VA 22313

EXPRESS MAIL CERTIFICATE UNDER 37 C.F.R. SECTION 1.10* Express Mail Tracking No. EV 307812695 US

Enclosed herewith please find:

- 1. A substitute nucleotide and/or amino acid sequence listing in written form as requested in an Office communication dated October 6, 2004. (25 pages)
- 2. A substitute nucleotide and/or amino acid sequence listing in computer readable form. (1 disk)
- 3. A statement indicating that the substitute paper sequence listing and substitute CRF are identical and include no new matter.(1 page)
- 4. Notice to comply w/requirements for Patent Applications containing nucleotide sequence and/or amino acid sequence disclosures. (1 page)
- 5. A self-addressed stamped postcard

I hereby certify that this correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service on November 1, 2004 (date), in an envelope as "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. Section 1.10, Mailing Label Number EV 307812695 US addressed to: Commissioner for Patents, Arlington, VA 22202.

(type or print name of person mailing paper)